News

Filter

Current filters:

AmgenNorth America

1 to 9 of 57 results

Amgen’s PCSK9 inhibitor evolocumab reduces cholesterol in Phase II study

Amgen’s PCSK9 inhibitor evolocumab reduces cholesterol in Phase II study

20-11-2013

USA-based biotech firm Amgen (Nasdaq: AMGN) has said its investigational PCSK9 inhibitor evolocumab helped…

AmgenBiotechnologyCardio-vascularevolocumabNorth AmericaResearchUSA

Amgen reports 24% rise in income with 11% growth in sales

Amgen reports 24% rise in income with 11% growth in sales

23-10-2013

Amgen has announced its third quarter results with an 11% growth in sales. Its net income was up 24%…

AmgenFinancialNorth AmericaPharmaceutical

Enbrel and Humira remain the mainstay for first-line biologic rheumatoid arthritis treatment in USA

19-09-2013

The vast majority of patients in the USA treated with Amgen's (Nasdaq: AMGN) Enbrel (etanercept) and…

AbbVieAmgenAnti-Arthritics/RheumaticsEnbrelHumiraMarkets & MarketingNorth AmericaPfizerPharmaceuticalXeljanz

Amgen's US deal with Servier cleared

13-08-2013

USA-based Amgen (Nasdaq: AMGN), the world's leading independent biotech firm, and privately-held French…

AmgenBiotechnologyCardio-vascularLicensingNorth AmericaPharmaceuticalProcoralanServier

Amgen gains rights to Servier's heart drugs ivabradine and S38844

10-07-2013

USA-based Amgen (Nasdaq: AMGN), the world's largest independent biotech firm, has entered a new collaboration…

AmgenBiotechnologyCardio-vascularEuropeivabradineLicensingNorth Americaomecamtiv mecarbilPharmaceuticalS38844Servier

FDA backs Amgen's Xgeva for new use, to treat giant cell tumor of the bone

14-06-2013

The US Food and Drug Administration late yesterday (June 13) expanded the approved use of biotech major…

AmgenBiotechnologyNorth AmericaOncologyRegulationXgeva

1 to 9 of 57 results

COMPANY SPOTLIGHT

Menarini

Back to top